Graphite Capital exits life sciences data platform Beacon

What's the deal? Graphite Capital has sold Beacon, a data platform serving the life sciences sector. The London-based private equity firm backed Beacon as part of its portfolio of mid-market investments, and has now exited the business.

Details on the buyer and transaction value have not been disclosed.

Why now? Life sciences data platforms have become hot property as pharmaceutical and biotech companies increasingly rely on data-driven decision-making. The sector has seen a wave of consolidation, with acquirers eager to snap up platforms that offer specialised datasets and analytics for drug development, clinical trials, and commercial strategy.

The signal: The sale reflects continued private equity appetite for health and life sciences data businesses — a corner of the market where sticky enterprise contracts and recurring revenue make for attractive exit multiples. For Graphite Capital, the deal marks another realisation from its mid-market portfolio, signalling confidence that buyer demand for data-rich platforms remains robust even in a more cautious dealmaking environment.

Read more: graphitecapital.com